Navigation Links
ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.
Date:7/7/2010

CHICAGO, July 7 /PRNewswire/ -- ICAP Ocean Tomo, the intellectual property brokerage division of ICAP plc (IAP.L), is offering for sale a patent portfolio related to the advanced drug formulation technology Captisol® owned by CyDex Pharmaceuticals Inc. The portfolio contains two US-issued patents and fifteen related foreign counterparts covering two important close-to-market, 505(b)(2), Captisol-enabled product opportunities: Captisol-enabled Fosphenytoin and Captisol-enabled Propofol.  

(Logo: http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100614/CG20517LOGO)

The advanced drug technology of CyDex's Captisol® is based on a modified cyclodextrin molecule that enables the creation of new products by significantly improving the solubility, stability, bioavailability, safety, and dosing of active pharmaceutical ingredients. Captisol-enabled™ Fosphenytoin is the advanced formulation of Fosphenytoin which is approved in the US for the short term treatment of epilepsy. This formulation offers advantages over the traditional product as it lowers pH and enables storage of the product at room temperature for up to two years. Captisol-enabled™ Propofol is an improved formulation over Propofol, an injectable general anesthetic. This formulation enhances the stability, reliability, and effectiveness of Propofol while reducing the potential for pain and allergic response. Unlike existing formulations, Captisol-enabled™ Propofol is pharmaceutically stable and does not degrade with exposure to light, oxidation, or the presence of divalent or trivalent cations.

"Both of these Captisol-enabled opportunities are very close to market and should be considered valuable assets to pharmaceutical manufacturers, distributors, branded generic companies, or specialty pharma companies looking to enhance their product offering, including those companies focused on injectable product opportunities," said Dean Becker, ICAP Ocean Tomo CEO.

To learn more about the patents available for sale in this portfolio or how to sell or buy intellectual property please contact Cameron Gray, Senior Vice President, ICAP Ocean Tomo at 650-421-3089 or at cameron.gray@us.icap.com.

About ICAP Ocean Tomo LLC

ICAP Ocean Tomo is the intellectual property brokerage division of ICAP.

About ICAP

ICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP is also the source of global market information and research for professionals in the international financial markets. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to www.icap.com.


'/>"/>
SOURCE ICAP Ocean Tomo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
2. Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing
3. Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
4. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
5. HealthWarehouse.com Now Offers Over 1,000 Medications Under $25 Bringing Increased Affordability to Consumers
6. BSGI Offers Improved Cancer Detection for Negative or Indeterminate Mammograms
7. In the Face of Pain® Offers Social Media 101 for Pain Management Advocates
8. Medicalequipmentpro.com Offers Fathers Day Discounts to Ensure this Fathers Day is a Healthy One
9. Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment
10. Gold Standard/Elsevier Offers Timely, Transparent, Reliable Drug Pricing Data, Including Average Wholesale Price (AWP)
11. Blog Contest Offers Graduate Students the Chance to Win a Trip to Zambia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- CSI Specialty Group (CSI) expanded its specialty pharmacy ... Pharmacy Podcast. A free, weekly show, the Specialty Pharmacy ... discussion and context amongst specialty pharmacy peers and professionals. ... The Specialty Pharmacy Podcast, hosted by industry leader ... DiMascio, CHE, CMCE, CPC, is available for streaming and/or ...
(Date:2/10/2016)... and SAN DIEGO , Feb. 10, ... global leader in viral gene therapy manufacturing, and Renova™ ... congestive heart failure and other chronic diseases, have entered ... manufacturing process and produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product ... --> --> This relationship ...
(Date:2/10/2016)... -- Urologix, the market leader for in-office minimally invasive ... (BPH), announces new private ownership and is operating as ... industry veteran of more than 20 years, has been ... Plymouth, Minn. The company,s two ... RF Therapy, will continue to be broadly available and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Sherly Sulaiman, certified clinical hypnotherapist and ... sessions to help Los Angeles-area actors cope with rejection, improve their auditions, and ... as “Mindfulness for Actors and Artists,” has been featured in Daily Actor ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO ... new 2.0 version at the International Roofing Expo in Orlando, Florida on February ... world's most advanced weather technology in the hands of consumers, roofing contractors, manufacturers ...
(Date:2/10/2016)... TX (PRWEB) , ... February 10, 2016 , ... ... commencement of a master charity program created to assist the local community. Pledging ... with community leaders and nonprofit organizations in the area. Their goal is to ...
(Date:2/10/2016)... ... 10, 2016 , ... Ongoing news of the ravages of traumatic brain injury ... a survey that takes a closer look at cases of TBI being managed by ... of TBI among the aging population, and identifies the challenges associated with their care. ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... the country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA ... volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny ...
Breaking Medicine News(10 mins):